Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Вторник, 21 октября 2008 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Физиотенз
Регистрация
Медицинские новости
Новая вакансия

Библиография

Включен в программу ОНЛС

  1. Armah Bl, Hofferber E, Stenzel W. General pharmacology of the novel centrally acting anti-hypertensive agent moxonidine. Arzneim Forsch 1988; 39 (10): 1426-1434
  2. Armann К, Greber D, Gharehbaghi H, et al. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries and cardiac interstitium. Am J Hypertens 1991; 5: 76-83
  3. Dominiak P. Historic espects in the identification of the li-receptor and the pharmacology of the imidazolines. In: Prichard BNC, Messerii FH, editors. Imidazolines and blood pressure control. Boston/Dordrecht/London: Kluwer Academic Publishers, 1994: 21-30
  4. Eichstadt H, Gatz G, Schroeder R, et al. Linksventrikulare hyper-trophieregression unter einer therapie mit moxonidin. Pharmacol Ther 1991; 1:12-17
  5. Ernsberger PR, Westbrooks KL, Christen МО, et al. A second generation of centrally acting antihypertensive agents act on putative 1,-imidazo- line receptors. J Cardiovasc Pharmacol 1992; 20 (SuppI 4): S. 1-10
  6. Frei M, Kuster L, Gardosch von Krosigk P-P, et al. Moxonidine and hydrochlorothiazide in combi- nation: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 (Supp11): S. 25-28
  7. Frisk-Holmberg M, Planitz V. A selective alpha2-adrenoceptor agonist in arterial essential hypertension. CurrTher Res 1987; 42:138-146
  8. Hamilton CA. Chemistry, mode of action and Experimental pharm-acology of moxonidine. In: van Zwieten PA et al, editors. The putative li-lmidazoline Receptor Agonist Moxonidine. 2nd Edition. London: Roy Soc Med, 1996:7-30
  9. Haxhiu MA, Dreshaj I, Erokwu B, et al. Vasodepressoin elicited in hypertensive rats by the selective I1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1992; 20 (SuppI 4): S. 11-15
  10. Haxhiu MA, Dreshaj I, Schafer SG, et al. The IT imidazoline agonist moxonidine is a selective cen- tral antihypertensive: lack of depressant action on central respiratory drive. Cardiovasc Drugs Ther 1993; 7 (Suppl 2):155(Abstr155)
  11. Huting J, Mitrovic V, Bahavar H, et al. Vergleich der wirkungen von moxonidin und nifedepin die linkventrikulare funktion bei monotherapie der essentiellen hypertonie. Herz Kreislauf 1992; 24:132-136
  12. Irzyniec Т, Mall G, Greber D, et al. Beneficial effect of nifedepine und moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 1992; 5: 437-443
  13. Julius S. Abnormalities of autonomic nervous control in human hypertension. In: Imidazolines and blood pressure control. In: Prichard BNC, Messerii FH, editors. Imidazolines and blood pressure control. Boston/Dordrecht/London: Kluwer Academic Publishers, 1994: 5-20
  14. Julius S. Report of a satellite symposium of the 3rd Congr Cardiovasc Dis Prevention. In: essential hypertension Number 5, Solvay healthcare Ltd. February 1997.
  15. Kaan EC, Bruckner R, Frohly P, et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Supp11): 19-27
  16. Kaan Ее. Data on file Solvay Healthcare Ltd, 1994. Kirch W, Hutt H-J, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15: 245-253
  17. Kirch W, Hutt H-J, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration to hypertensive patients. J Clin Phatmacol 1990; 30:1088-1095
  18. Kraft К, Vetter H. Twenty-four-hour blood pressure profilies in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovacs Pharmacol 1994; 24 (Supp11): S.29-33
  19. Kuppers HE, Jager BA, Luszick JH, et al. Placebocontrolled comparsion of the efficacy and tolerability of onve=daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertension 1997; 15: 93-97
  20. Lithell H. Moxonidine improves insulin resistance in obese, insulin resistant hypertensive patients, 17th ISH, Amsterdam, June 7,1998
  21. Lotti G, Gianrossi R. Moxonidin vs. Captopril bei leichter bis mittelschwerer hypertonie. Fortschr Med 1993; 111 (27): 429-432
  22. Mangiameli S, Privetera A, Jonte G, Low-Kroger A. Behandlung der leichten bis mittelschweren hypertonie. Z Allg Med 1992; 68: 862-866
  23. Messerii FH. Introduction: Anti-hypertensive therapy: Past, present, and future. In Imidazolines and blood pressure control. In: Prichrad BNC, Messerii FH, editors. Imidazolines and blood pressure control. Boston/Dordrwcht/London: Kluwer Academic Publishers, 1994:1-4
  24. Michel MC, Schafers R. From o^-adrenoceptors to imidazoline receptors: putative progress for cardiovascular therapy. J Cardiovasc Pharmacol 1992; 20 (SuppI 4):S.24-S.30
  25. Mitrovic V, Patyna W, Hiiting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-972
  26. Moan A, Nordby G, Rostrup M, et al. Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men. Am J Hypertension 1995; 8: 268-275
  27. Ollivier JP, Christen МО, Schafer SG. Moxonidine: a second generation of centrally acting drugs. J Cardiovac Pharmacol 1992; 20 (SuppI 4): S.31-S.36
  28. Ongyert D, Dotzer F. Wirksamkeit und vertraglichkeit von moxonidin. Zeit Allgemeinmed 1993; 69: S.56-S.60
  29. Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comprasion of moxonidine and atenol in the management of patients with mild-to-moderate hypertension. J Cardiovacs Pharmacol 1992; 20 (SuppI 4): S.45-S.49
  30. Prichard BNC. Preface-progress in the treatment of hypertension. In: Prichard BNC, Messerii FH, editors. Imidazolines and blood pressure control. Boston/Dordrecht/London: Kluwer Academic Publishers, 1994: ix-x
  31. Prichard BNC. (1996a) Clinical pharmacology of moxonidine. In: van Zwieten PA et al, editors. The I1-Imidazoline Receptor Agonist Moxonidine. 2nd Edition. London: Roy Soc Med, 1996: 31-47
  32. Prichard BNC. (1996b) Clinical experience with moxonidine. In: van Zweiten PA et al, editors. The I1-Imidazoline Receptor Agonist Moxonidine. 2nd Edition. London: Roy Soc Med, 1996: 49-75
  33. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenal system. New EngI J Med 1996; 334: 374-381
  34. Robertson JIS. Data on File. Solvay Healthcare Ltd, 1997.
  35. Rupp H, Jacob R. Excess catechol-amines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Medical Hypotheses 1995; 44: 217-225
  36. Schachter M. The sympathetic nervous system and hypertension. Martin Dunitz Ltd, London, 1997.
  37. Schafers RF, Low-Kroger A, Philipp Th. Wirksamkeit und vertraglichkeit des neuen zentralwirksamen antihypertensivums moxonidin im vergleich zu enalapril. Nieren- und Hochdruckkrankheiten 1994; 23(5): S.221-224
  38. Schmidt U, Frerick H, Kraft K, et al. Hypertension: a possible risk in road traffic. J Cardiovacs Pharmacol 1992; 20 (SuppI 4):S.50-56
  39. Schwarz W, Kandziora J. Langzeiterfahrungen mit moxonidin, einem neuen anti-hypertensivum. Fortschr Med 1990; 32: S.616-620
  40. Gregory D. Sides, Monika I. Leschinger, Rainer Walenta and John L. McNay, Jr.; Rev. Contemp. Pharmacother. 1998; 9: 491-499
  41. Theodor R, Weimann H-J, Weber W, et al. Absolute bio-availability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16(2): 153-159
  42. Trenk D, Wagner F, Jahnchen E, et al. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol 1987; 27: 988-993
  43. Trieb G, Jager B, Hughes PR, et al. Long-term evaluation of the antihypertensive efficacy and tolerability of the orally acting imidazoline li receptor agonist moxonidine in patients with mild-to-moderate essential hypertension. Eur J Clin Res 1995; 7: 227-240
  44. Wimann H-J, Rudolph M. Clinical pharmacokinetics of moxonidine. J Cardiovacs Pharmacol 1992; 20 (SuppI 4):S.37-41
  45. Wilkens H, Wilkens JH, Fabel H. Die wirkung von moxonidin - einem zentral wirksamen antihypertensivum - auf atemregulation und histamin-reaktivitat. Kardio1992; 10:1-4
  46. Wolf R. The treatment of hypertensive patients with a xalcium antagonist or moxonidine: a comprasion. J Cardiovacs Pharmacol 1992; 20 (SuppI 4): S.42-44



Solvay Pharma
Баннерная сеть Солвей-Фарма.ру
Адрес


Последнее обновление  21.10.2008 г.